New drug combo aims to fight lung cancer after chemoradiation
NCT ID NCT07091305
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the drug QL1706 to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. QL1706 is a type of immunotherapy that targets two immune checkpoints to help the body fight cancer. The study will enroll 28 participants and measure how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QL1706 (a drug that targets two immune checkpoints, PD-1 and CTLA-4)
What this could lead to
If successful, this could offer a new treatment option that improves how long people with limited-stage small cell lung cancer live without their cancer getting worse.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. The drug combination can cause serious immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMORADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••